MIRA INFORM REPORT
|
Report No. : |
356120 |
|
Report Date : |
26.12.2015 |
IDENTIFICATION DETAILS
|
Name : |
MAPBIOPHARMA
SL |
|
|
|
|
Registered
Office : |
AV/
Manoteras, 30 - Edificio B, Planta 1 Oficina 124 - Madrid - 28050 - Madrid |
|
|
|
|
Country : |
Spain |
|
|
|
|
Financials (as
on) : |
2014 |
|
|
|
|
Date of
Incorporation : |
10.10.2014 |
|
|
|
|
Legal Form : |
Private Company |
|
|
|
|
Line of Business
: |
Wholesale
of pharmaceutical goods |
|
|
|
|
No. of Employee
: |
2 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome
financial difficulties seems comparatively below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment
Behaviour : |
Slow but correct |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous
Rating (31.12.2014) |
Current
Rating (31.03.2015) |
|
Spain |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SPAIN - ECONOMIC OVERVIEW
After experiencing a prolonged recession in the wake of the global financial crisis that began in 2008, in 2014 Spain marked the first full year of positive economic growth in seven years, largely due to increased private consumption. At the onset of the global financial crisis Spain's GDP contracted by 3.7% in 2009, ending a 16-year growth trend, and continued contracting through most of 2013. In 2013 the government successfully shored up struggling banks - exposed to the collapse of Spain's depressed real estate and construction sectors - and in January 2014 completed an EU-funded restructuring and recapitalization program.
Until 2014, credit contraction in the private sector, fiscal austerity, and high unemployment weighed on domestic consumption and investment. The unemployment rate rose from a low of about 8% in 2007 to more than 26% in 2013, but labor reforms prompted a modest reduction to 23.7% in 2014. High unemployment strained Spain's public finances, as spending on social benefits increased while tax revenues fell. Spain’s budget deficit peaked at 11.4% of GDP in 2010, but Spain gradually reduced the deficit to just under 7% of GDP in 2013-14, slightly above the 6.5% target negotiated between Spain and the EU. Public debt has increased substantially – from 60.1% of GDP in 2010 to more than 97% in 2014.
Exports were resilient throughout the economic downturn and helped to bring Spain's current account into surplus in 2013 for the first time since 1986, where it remained in 2014. Rising labor productivity and an internal devaluation resulting from moderating labor costs and lower inflation have helped to improve foreign investor interest in the economy and positive FDI flows have been restored.
The government's efforts to implement labor, pension, health, tax, and education reforms - aimed at supporting investor sentiment - have become overshadowed by political activity in 2015 in anticipation of the national parliamentary elections in November. Spain’s 2015 budget, published in September 2014, rolls back some recently imposed taxes in advance of the elections and leaves untouched the country’s value-added tax (VAT) regime, which continues to generate significantly lower revenue than the EU average. Spain’s borrowing costs are dramatically lower since their peak in mid-2012, and despite the recent uptic in economic activity, inflation has dropped sharply, from 1.5% in 2013 to nearly flat in 2014.
|
Source : CIA |
EXECUTIVE
SUMMARY
|
|
|
|
Name: |
MAPBIOPHARMA SL |
|
NIF /
Fiscal code: |
B87108353 |
|
Status: |
ACTIVE |
|
Incorporation
Date: |
10/10/2014 |
|
Register Data |
Register
Section 8 Sheet 589359 |
|
Last Publication in BORME: |
16/09/2015
[Increase of Capital] |
|
Last
Published Account Deposit: |
2014 |
|
Share
Capital: |
225.971 |
|
|
|
|
Localization: |
AV/
MANOTERAS, 30 - EDIFICIO B, PLANTA 1 OFICINA 124 - MADRID - 28050 - MADRID |
|
Telephone
- Fax - Email - Website: |
Telephone.
912438563 Email. info@mapbiopharma.es Website. www.mapbiopharma.es |
|
|
|
|
Activity: |
|
|
NACE: |
4646 -
Wholesale of pharmaceutical goods |
|
Registered
Trademarks: |
|
|
Audited
/ Opinion: |
No |
|
Tenders
and Awards: |
|
|
Subsidies: |
0 for
a total cost of 0 |
|
Main
products / services: |
Own registriesDermatological
textilesFood components |
|
Quality
Certificate: |
No |
|
|
|
|
Payment
Behaviour: |
According
to the agreed terms |
|
Prospects: |
Consolidation |
|
Industry
situation: |
Maturity |
|
|
|
|
Defaults, Legal Claims and Insolvency
Proceedings : |
|
|
|
|
|
|
|
Number |
Amount
(€) |
Most
Recent Entry |
|
Insolvency
Proceedings, Bankruptcy and Suspension of Payments |
|
Unpublished |
--- |
--- |
|
Defaults
on debt with Financial Institutions and Large Companies |
|
None |
--- |
--- |
|
Judicial
Claims (Notices, Executive Proceedings, Attachments, Auctions, Bad Debt) |
|
None |
0 |
--- |
|
Proceedings
heard by the Civil Court |
|
Unpublished |
0 |
--- |
|
Proceedings
heard by the Labour Court |
|
Unpublished |
0 |
--- |
|
|
|
Partners: |
|
|
|
Shares: |
0 |
|
|
Other
Links: |
3 |
|
|
No. of
Active Corporate Bodies: |
SINGLE
ADMINISTRATOR 1 |
|
|
|
|
|
Guarantees: |
|
|
Properties
Registered: |
Company
NO, Administrator NO |
|
Financing
/ Guarantee Sources : |
Sources
YES, Guarantees NO |
|
|
|
|
|
|
|
INVESTIGATION SUMMARY |
|
|
It is
a company incorporated the 01-10-2014, engaged in the wholesale of raw materials
and finished products for the pharmaceutical, veterinary and nutritional
industry. Its commercial scope is national. The consulted sources do not have
any bad comment about it but being short commercial life we recommend a close
follow up of company's evolution in order to assign for the future a
commercial credit limit according to its volume and compliance. |
|
|
Interviewed
Person: |
|
|
Enquiry Details |
|
Identification
|
|
|
Social Denomination: |
MAPBIOPHARMA
SL |
|
NIF / Fiscal code: |
B87108353 |
|
Corporate Status: |
ACTIVE |
|
Start of activity: |
2014 |
|
Registered Office: |
AV/
MANOTERAS, 30 - EDIFICIO B, PLANTA 1 OFICINA 124 |
|
Locality: |
MADRID |
|
Province: |
MADRID |
|
Postal Code: |
28050 |
|
Telephone: |
912438563 |
|
Fax: |
912438562 |
|
Website: |
www.mapbiopharma.es |
|
Email: |
info@mapbiopharma.es |
|
Interviewed Person: |
Mr.
Miguel Ara |
Branch
Offices
|
|
|
-- |
|
Activity
|
NACE: |
4646 |
|
Corporate Purpose: |
IMPORT, EXPORT, WHOLESALE AND RETAIL SALE OF CHEMICALS, PHAMACEUTICS AND SPECIALTIES FOR HUMAN, VETERINARY AND COSMETIC USE. CHEMICALS, DRUGS AND BIOTEHCNOLOGY PRODUCTS IN ANY OF THEIR PRODUCTION PHASES. |
|
Additional Information: |
Supply of raw materials and finished products for the pharmaceutical, veterinary and nutritional industry. |
|
Additional Address: |
AV/ MANOTERAS, 30 - EDIFICIO B, PLANTA 1 OFICINA 124, 28050 MADRID, registered office and offices. |
|
Franchise: |
No |
|
Import / export: |
IMPORT / EXPORT |
|
Future Perspective: |
Consolidation |
|
Industry situation: |
Maturity |
Main
products / services
|
|
|
|
|
|
Product |
% Over
Sales |
|
Own
registries |
|
|
Dermatological
textiles |
|
|
Food
components |
|
|
Human
APIS |
|
|
Veterinary
APIS |
|
|
|
|
|
Number
of Employees
|
|
|
|
|
|
|
Year |
No. of
employees |
Established |
Incidentals |
|
|
|
2015 |
2 |
|
|
|
The data
of employees is from the latest available financial statements. Failing that,
are estimates data calculated by statistical methods
|
Chronological
Summary
|
|||
|
|
|
|
|
|
|
Year |
Act |
|
|
|
2014 |
Appointments/
Re-elections (1) Company Formation (1) Other Concepts/ Events (1) |
|
|
|
2015 |
Accounts
deposit (year 2014) Increase of Capital (3) |
|
|
|
|
|
|
|
|
|
|
|
Breakdown
of Owners' Equity
|
|
|
Registered Capital: |
225.971 |
|
Paid up capital: |
225.971 |
Active
Social Bodies
|
|
|
|
|
|
Post
published |
Social
Body's Name |
Appointment
Date |
Other
Positions in this Company |
|
SINGLE
ADMINISTRATOR |
CABASI
INVERSIONES SL |
23/10/2014 |
1 |
|
REPRESENTATIVE |
ARA
PARGA MIGUEL |
23/10/2014 |
1 |
|
|
|
|
|
Defaults,
Legal Claims and Insolvency Proceedings
|
|
|
|
|
Section
enabling assessment of the degree of compliance of the company queried with its
payment obligations. It provides information on the existence and nature of all
stages of Insolvency and Legal Proceedings published with reference to the
Company in the country's various Official Bulletins and national newspapers, as
well Defaults Registered in the main national credit bureaus (ASNEF Industrial
and RAI ).
>
Summary
Chronological
summary
|
|
|
Number
of Publications |
Amount
(_) |
Start
date |
End
date |
|
Insolvency
Proceedings, Bankruptcy and Suspension of Payments |
|
Unpublished |
--- |
--- |
--- |
|
Request/Declaration |
|
0 |
--- |
date |
|
|
Proceedings |
|
--- |
--- |
|
--- |
|
Resolution |
|
--- |
--- |
|
--- |
|
Defaults
on debt with Financial Institutions and Large Companies |
Bank and
Commercial Delinquency |
None |
0 |
|
|
|
Status:
Friendly |
|
--- |
|
|
|
|
Status:
Pre-Litigation |
|
--- |
|
|
|
|
Status:
Litigation |
|
--- |
|
|
|
|
Status:
Non-performing |
|
--- |
|
|
|
|
Status:
insolvency proceedings, bankruptcy and suspension of payments |
|
--- |
|
|
|
|
Other
status |
|
--- |
|
|
|
|
Legal
and Administrative Proceedings |
|
Unpublished |
--- |
|
|
|
Notices
of defaults and enforcement |
|
--- |
--- |
|
--- |
|
Seizures |
|
--- |
--- |
|
--- |
|
Auctions |
|
--- |
--- |
|
--- |
|
Declarations
of insolvency and bad debt |
|
--- |
--- |
|
--- |
|
Proceedings
heard by the Civil Court |
|
Unpublished |
--- |
|
|
|
Proceedings
heard by the Labour Court |
|
Unpublished |
--- |
|
|
>
Details
>
Basis for scoring
|
Positive Factors |
Adverse Factors |
|
No judicial claims have been detected in the Official Gazettes, regarding any Entity's outstanding debts with the Tax Bureau or Social Security administrations, as submitted by Courts of the various court jurisdictions. No irregular payment performance has been detected based on information obtained from credit bureaus. Significant level of financial autonomy. The asset is financed mostly with equity and financing with maturity exceeding one year, providing a solid financial structure. The current debt represents a 42.95of the financial structure. In principle, a decrease in this ratio would indicate an improvement in the short-term financial situation. Positive Working CapitalThe Company's Working Capital quality is significant, i.e. much of the Company financing comes from its equity. A structure is considered optimal if its liquidity level is slightly above its debt volume as a result of low idleness levels of its financial resources involved. |
It does not have any financial profitability.. MAPBIOPHARMA SL It does not obtain any financial return as a consequence of its subscribed capital which, a priori, might deteriorate its financial and economic situation. It presents a poor productivity. Net margin shows an inappropriate company costs management as operating expenses exceed income. Sales profitability. The volume of business generated during the financial year was not enough to cover the expenses before considering the tax effect. Imbalance in levels of realizable assets . The ratio of current assets represented by stocks and Treasury is considered insufficient to meet current obligations, denoting particular concentration of current assets in the receivables to obtain cash, which determines high dependence on monetization of balance current debtors. Private consumption continues to have, in spite of some signs of improvement, very low rates , thus showing great weakness. |
Probability of default
|
|
|
|
|
>
Estimated Probability of Default for the next 12 months: 1.262 %
|
Sector
in which comparison is carried out: 464 Wholesale
of household goods |
|
The
company's comparative analysis with the rest of the companies that comprise the
sector, shows the company holds a better position with regard to the
probability of non-compliance.
The
93.00% of the companies of the sector MAPBIOPHARMA SL belongs to show a higher
probability of non-compliance.
The
probability of the company's non-compliance with its payment obligations within
deadlines estimated by our qualifications models is 1.262%.
In the
event they fail to comply with the payment, the seriousness of the loss will
depend on factors such as the promptness of the commencement of the charging
management, the existence of executive documents which match the credit or the
existence of guarantees and free debt assets under the name of the debtor.
Therefore, the probability of non-compliance should not be solely interpreted
as the total loss of the owed amount.
|
Result of query submitted
to the R.A.I. (Spanish Bad Debt Register) on |
LEGAL
CLAIMS
|
|
Summary of Judicial Claims |
|
|
|
|
|
|
|
Not published |
|
|
|
Not published |
|
|
|
|
|
|
|
Not published |
|
|
|
Not published |
|
|
|
Not published |
|
|
|
Not published |
|
|
|
|
|
|
|
Not published |
|
|
|
Not published |
|
|
|
|
|
|
|
Not published |
Guarantees
|
|
|
References
|
|
|
|
|
|
Suppliers |
|
|
|
Name |
NIF |
Telephone |
|
|
|
BIOCON (INDIA) |
|
|
|
|
|
DIVI (INDIA) |
|
|
|
|
Link
List
|
|
HAS IN ITS
ADMINISTRATION BOARD TO: |
1 Entities |
|
IS RELATED
WITH: |
2 Entities |
> Other
relationships
|
Relationship |
Entity |
Province |
Shareholding
stake |
|
IS RELATED
WITH |
CABASI
INVERSIONES SL |
MADRID |
|
|
|
ESSENTIALIS SL |
MADRID |
|
|
HAS IN ITS
ADMINISTRATION BOARD TO |
CABASI
INVERSIONES SL |
MADRID |
|
Turnover
|
|
|
Total Sales 2014 |
313.220,90 |
The sales data
is from the latest available financial statements. Failing that, are estimates data
calculated by statistical methods.
|
Financial
Accounts and Balance Sheets
|
Financial Years Presented
|
Ejercicio |
Tipo de Cuentas Anuales |
Fecha Presentacion |
|
2014 |
Normales |
July 2015 |
The data in the report regarding the last Company Accounts submitted by the company is taken from the TRADE REGISTER serving the region in which the company's address is located 31/12/2014
> Balance en formato Abreviado de acuerdo al Nuevo Plan
General Contable 2007
Information
corresponding to the fiscal year 2014 is taken from information submitted
to the TRADE REGISTER. Data corresponding to fiscal years before 2014 has
been compiled based on the equivalence criteria stipulated in Act JUS/206/2009.
Where the provisions of the Act did not establish relevant equivalence
criteria. To view details on the methodology.
|
|
ORIGINAL |
|
|
Assets |
2014 |
|
|
A) NON-CURRENT ASSETS: 11000 |
13.265,00 |
|
|
I. Intangible fixed assets : 11100 |
803,00 |
|
|
II. Tangible fixed assets : 11200 |
5.251,00 |
|
|
III. Real estate investment: 11300 |
0,00 |
|
|
IV. Long-term investments in Group
companies and associates : 11400 |
0,00 |
|
|
V. Long-term financial investments:
11500 |
7.211,00 |
|
|
VI. Assets for deferred tax : 11600 |
0,00 |
|
|
VII. Non-current trade debtors :
11700 |
0,00 |
|
|
B) CURRENT ASSETS: 12000 |
356.722,00 |
|
|
I. Non-current assets held for sale :
12100 |
0,00 |
|
|
II. Stocks: 12200 |
0,00 |
|
|
III. Trade debtors and others receivable
accounts: 12300 |
328.418,00 |
|
|
1.- Customers for
sales and provisions of services : 12380 |
323.087,00 |
|
|
a) Long-term receivables from sales and services supplied : 12381 |
0,00 |
|
|
b) Customers for sales and provisions of services : 12382 |
323.087,00 |
|
|
2.- Called up share capital
: 12370 |
0,00 |
|
|
3.- Other accounts
receivable : 12390 |
5.331,00 |
|
|
IV. Short-term investments in Group
companies and associates: 12400 |
0,00 |
|
|
V. Short-term financial investments :
12500 |
0,00 |
|
|
VI. Short-term accruals: 12600 |
0,00 |
|
|
VII. Cash and other equivalent liquid
assets : 12700 |
28.303,00 |
|
|
TOTAL ASSETS (A + B) : 10000 |
369.987,00 |
|
|
|
ORIGINAL |
|
|
Liabilities and Net
Worth |
2014 |
|
|
A) NET WORTH: 20000 |
173.586,00 |
|
|
A1) Shareholders' equity :
21000 |
173.586,00 |
|
|
I. Capital:
21100 |
173.673,00 |
|
|
1.- Registered capital: 21110 |
173.673,00 |
|
|
2.-
(Uncalled capital) : 21120 |
0,00 |
|
|
II. Share premium:
21200 |
0,00 |
|
|
III. Reserves:
21300 |
0,00 |
|
|
IV. (Common stock
equity): 21400 |
0,00 |
|
|
V. Profit or loss brought
forward: 21500 |
0,00 |
|
|
VI. Other
shareholders' contributions: 21600 |
0,00 |
|
|
VII. Result of the
period: 21700 |
-87,00 |
|
|
VIII. (Interim
dividend): 21800 |
0,00 |
|
|
IX. Other net worth
instruments: 21900 |
0,00 |
|
|
A-2) Adjustments due to changes in value:
22000 |
0,00 |
|
|
A-3) Received subsidies, donations and
legacies: 23000 |
0,00 |
|
|
B) NON-CURRENT LIABILITIES: 31000 |
37.500,00 |
|
|
I. Long-term provisions: 31100 |
0,00 |
|
|
II. Long-term creditors : 31200 |
37.500,00 |
|
|
1.- Amounts owed to
credit institutions: 31220 |
0,00 |
|
|
2.- Creditors from
financial leasing : 31230 |
0,00 |
|
|
3.- Other long-term
creditors : 31290 |
37.500,00 |
|
|
III. Long-term debts with Group companies
and associates: 31300 |
0,00 |
|
|
IV. Liabilities for deferred tax:
31400 |
0,00 |
|
|
V. Long-term accruals: 31500 |
0,00 |
|
|
VI. Non-current trade creditors :
31600 |
0,00 |
|
|
VII. Special long-term debts : 31700 |
0,00 |
|
|
C) CURRENT LIABILITIES : 32000 |
158.901,00 |
|
|
I. Liabilities linked to non-current assets
held for sale : 32100 |
0,00 |
|
|
II. Short-term provisions: 32200 |
0,00 |
|
|
III. Short-term creditors : 32300 |
143.160,00 |
|
|
1.- Amounts owed to credit
institutions: 32320 |
143.160,00 |
|
|
2.- Creditors from
financial leasing : 32330 |
0,00 |
|
|
3.- Other short-term
creditors : 32390 |
0,00 |
|
|
IV. Short-term debts with Group companies and
associates: 32400 |
0,00 |
|
|
V. Trade creditors and other accounts
payable: 32500 |
15.741,00 |
|
|
1.- Suppliers:
32580 |
707,00 |
|
|
a) Long-term debts : 32581 |
0,00 |
|
|
b)
Short-term debts : 32582 |
707,00 |
|
|
2.- Other creditors :
32590 |
15.034,00 |
|
|
VI. Short-term accruals: 32600 |
0,00 |
|
|
VII. Special short-term debts : 32700 |
0,00 |
|
|
TOTAL NET WORTH AND LIABILITIES (A + B + C) : 30000 |
369.987,00 |
|
|
|
ORIGINAL |
|
|
Profit and Loss |
2014 |
|
|
1. Net turnover: 40100 |
313.221,00 |
|
|
2. Changes in stocks of finished goods and
work in progress: 40200 |
0,00 |
|
|
3. Works carried out by the company for its
assets: 40300 |
0,00 |
|
|
4. Supplies : 40400 |
-280.575,00 |
|
|
5. Other operating income: 40500 |
0,00 |
|
|
6. Personnel costs: 40600 |
-4.746,00 |
|
|
7. Other operating costs: 40700 |
-32.499,00 |
|
|
8. Amortisation of fixed assets:
40800 |
-432,00 |
|
|
9. Allocation of subsidies of non-financial
fixed assets and other: 40900 |
0,00 |
|
|
10. Excess provisions : 41000 |
0,00 |
|
|
11. Impairment and result of transfers of
fixed assets: 41100 |
0,00 |
|
|
12. Negative difference in combined
businesses: 41200 |
0,00 |
|
|
13. Other results : 41300 |
0,00 |
|
|
A) OPERATING INCOME (1 + 2 + 3 + 4 + 5 + 6 + 7 + 8 + 9 + 10 + 11
+ 12 + 13) : 49100 |
-5.031,00 |
|
|
14. Financial income : 41400 |
2,00 |
|
|
a) Allocation of
financial subsidies, donations and legacies: 41430 |
0,00 |
|
|
b) Other financial
income: 41490 |
2,00 |
|
|
15. Financial expenditure: 41500 |
-277,00 |
|
|
16. Changes in fair value of financial
instruments : 41600 |
0,00 |
|
|
17. Exchange rate differences : 41700 |
5.219,00 |
|
|
18. Impairment and result for transfers of
financial instruments: 41800 |
0,00 |
|
|
19. Other financial income and expenditure:
42100 |
0,00 |
|
|
a) Incorporation of
financial expenditure to assets: 42110 |
0,00 |
|
|
b) Financial income
from arrangement with creditors: 42120 |
0,00 |
|
|
c) Other income and
expenditure: 42130 |
0,00 |
|
|
B) FINANCIAL REVENUE (14 + 15 + 16 + 17 + 18 + 19) : 49200 |
4.944,00 |
|
|
C) NET RESULT BEFORE TAXES (A + B) : 49300 |
-87,00 |
|
|
20. Income taxes: 41900 |
0,00 |
|
|
D) RESULT OF THE PERIOD (C + 20) : 49500 |
-87,00 |
|
CASHFLOW
STATEMENT
|
|
|
|
|
Model: Normal
> Source of information: Data contained in this section is
taken from the information declared in the Annual Accounts submitted to the
Trade Register.
|
|
2014 |
|
|
1. Fiscal year result before taxes.: 61100 |
-87,00 |
|
|
2. Results adjustments.: 61200 |
707,00 |
|
|
a) Fixed Assets Amortization (+).:
61201 |
432,00 |
|
|
g) Financial income (-).: 61207 |
-2,00 |
|
|
h) Financial Expenses (+). : 61208 |
277,00 |
|
|
3. Changes in current capital equity.: 61300 |
-312.678,00 |
|
|
d) Debtors and other accounts receivable
(+/-). : 61302 |
-328.418,00 |
|
|
d) Creditors and other accounts payable
(+/-). : 61304 |
15.741,00 |
|
|
4. Other cash flows for operating activities.: 61400 |
-275,00 |
|
|
a) Interest payments (-). : 61401 |
-277,00 |
|
|
c) Interest collection (+). : 61403 |
2,00 |
|
|
5. Operating activity cash flows (1 + 2 + 3 + 4) : 61500 |
-312.333,00 |
|
|
6. Payments for investment (-).: 62100 |
-13.265,00 |
|
|
b) Intangible fixed assets. : 62102 |
-803,00 |
|
|
c) Fixed assets. : 62103 |
-5.251,00 |
|
|
e) Other financial assets. : 62105 |
-7.211,00 |
|
|
7. Divestment payment collection (+). : 62200 |
0,00 |
|
|
8. Investment activity cash flows (6 + 7) minus Amortization:
62300 |
-13.697,00 |
|
|
9. Payment collection and payments for equity instruments. :
63100 |
173.673,00 |
|
|
a) Issuance of equity instruments (+). :
63101 |
173.673,00 |
|
|
10. Payment collection and payments for financial liabilities
instruments.: 63200 |
180.660,00 |
|
|
a) Issuance : 63201 |
180.660,00 |
|
|
2. Debts incurred with credit institutions
(+). : 63203 |
143.160,00 |
|
|
5. Other debts (+). : 63206 |
37.500,00 |
|
|
11. Payments from dividends and remunerations from other assets
instruments. : 63300 |
0,00 |
|
|
12. Cash flows for financing activities (9+10+11).: 63400 |
354.333,00 |
|
|
D) EFFECT OF EXCHANGE RATE CHANGES: 64000 |
0,00 |
|
|
E) NET INCREASE/DECREASE OF CASH OR EQUIVALENT ASSETS
(+/-5+/-8+/12+/-D) : 65000 |
28.303,00 |
|
|
Cash or equivalent assets as of end of the fiscal year.:
65200 |
28.303,00 |
|
|
FINANCIAL
DIAGNOSIS
|
|
|
|
|
> Economic-Financial Comparative Analysis
Data used in the following ratios and indicators is taken
from the Annual Accounts submitted by the company to the TRADE REGISTER.
> Comparison within the Sector
|
Cash Flow |
2014 |
Variación 2014 - |
|
||
|
|
Empresa |
Sector |
Empresa |
Sector |
|
|
Cash Flow over Sales: |
0,09 % |
0,00 % |
NaN % |
NaN % |
|
|
EBITDA over Sales: |
-1,47 % |
7,07 % |
NaN % |
NaN % |
|
|
Cash Flow Yield: |
0,08 % |
0,00 % |
NaN % |
NaN % |
|
|
Profitability |
2014 |
Variación 2014 - |
|
||
|
|
Empresa |
Sector |
Empresa |
Sector |
|
|
Operating economic profitability: |
-1,39 % |
1,49 % |
NaN % |
NaN % |
|
|
Total economic profitability: |
0,05 % |
1,25 % |
NaN % |
NaN % |
|
|
Financial profitability: |
-0,05 % |
-0,37 % |
NaN % |
NaN % |
|
|
Margin: |
-1,61 % |
2,36 % |
NaN % |
NaN % |
|
|
Mark-up: |
-0,03 % |
-0,18 % |
NaN % |
NaN % |
|
|
Solvency |
2014 |
Variación 2014 - |
|
||
|
|
Empresa |
Sector |
Empresa |
Sector |
|
|
Liquidity: |
0,18 |
0,20 |
NaN |
NaN |
|
|
Acid Test: |
2,24 |
0,92 |
NaN |
NaN |
|
|
Working Capital / Investment: |
0,53 |
0,10 |
NaN |
NaN |
|
|
Solvency: |
2,24 |
1,48 |
NaN |
NaN |
|
|
Indebtedness |
2014 |
Variación 2014 - |
|
||
|
|
Empresa |
Sector |
Empresa |
Sector |
|
|
Indebtedness level: |
1,13 |
0,98 |
NaN |
NaN |
|
|
Borrowing Composition: |
0,24 |
1,08 |
NaN |
NaN |
|
|
Repayment Ability: |
6,94 |
1.972,90 |
NaN |
NaN |
|
|
Warranty: |
1,88 |
2,03 |
NaN |
NaN |
|
|
Generated resources / Total creditors: |
0,00 |
0,04 |
NaN |
NaN |
|
|
Efficiency |
2014 |
Variación 2014 - |
|
||
|
|
Empresa |
Sector |
Empresa |
Sector |
|
|
Productivity: |
0,03 |
1,33 |
NaN |
NaN |
|
|
Turnover of Collection Rights : |
0,95 |
3,95 |
NaN |
NaN |
|
|
Turnover of Payment Entitlements: |
19,89 |
2,78 |
NaN |
NaN |
|
|
Stock rotation: |
|
2,86 |
NaN |
NaN |
|
|
Assets turnover: |
0,86 |
0,63 |
NaN |
NaN |
|
|
Borrowing Cost: |
0,14 |
2,53 |
NaN |
NaN |
|
> Trend of indicators under the General Accounting Plan of 2007
(2014)
|
Cash Flow |
2014 |
|
|
Cash Flow over Sales: |
0,09 % |
|
|
EBITDA over Sales: |
-1,47 % |
|
|
Cash Flow Yield: |
0,08 % |
|
|
Profitability |
2014 |
|
|
Operating economic profitability: |
-1,39 % |
|
|
Total economic profitability: |
0,05 % |
|
|
Financial profitability: |
-0,05 % |
|
|
Margin: |
-1,61 % |
|
|
Mark-up: |
-0,03 % |
|
|
Solvency |
2014 |
|
|
Liquidity: |
0,18 |
|
|
Acid Test: |
2,24 |
|
|
Working Capital / Investment: |
0,53 |
|
|
Solvency: |
2,24 |
|
|
Indebtedness |
2014 |
|
|
Indebtedness level: |
1,13 |
|
|
Borrowing Composition: |
0,24 |
|
|
Repayment Ability: |
6,94 |
|
|
Warranty: |
1,88 |
|
|
Generated resources / Total creditors: |
0,00 |
|
|
Efficiency |
2014 |
|
|
Productivity: |
0,03 |
|
|
Turnover of Collection Rights : |
0,95 |
|
|
Turnover of Payment Entitlements: |
19,89 |
|
|
Assets turnover: |
0,86 |
|
|
Borrowing Cost: |
0,14 |
|
COMPARATIVE
SECTORIAL BALANCE
|
|
|
|
|
Sector-based Comparison
under the rules of the New General Accounting Plan.
|
|
Variación - |
|
|
|
Empresa |
Sector |
|
|
Variación - |
|
|
|
Empresa |
Sector |
|
|
Variación - |
|
|
|
Empresa |
Sector |
|
News
|
|
Public
Tenders and Works Won
|
No Public Tenders assigned to the name of the company.
Research
Summary
|
|
It is a company incorporated the 01-10-2014, engaged in the wholesale of raw materials and finished products for the pharmaceutical, veterinary and nutritional industry. Its commercial scope is national. The consulted sources do not have any bad comment about it but being short commercial life we recommend a close follow up of company's evolution in order to assign for the future a commercial credit limit according to its volume and compliance. |
|
Sources
|
|
Registry of Commerce's Official Gazette. Own and external
data bases Company References |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.20 |
|
|
1 |
Rs.98.30 |
|
Euro |
1 |
Rs.72.41 |
|
Euro |
1 |
Rs.72.55 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
KAS |
|
|
|
|
Report Prepared
by : |
TRU |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history (10%) Market trend (10%) Operational size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.